HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 914-920

  Roquebert, B ^a,b,c   Damond, F ^a,c   Collin, G ^a,c   Matheron, S ^a,b   Peytavin, G ^a   Benard A ^c   Campa, P ^d   Chene G ^c   Brun Vezinet F ^a,b,c   Descamps, Diane ^a,b,c  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

HIV AIDS; Human immunodeficiency virus type 2; Mutations; Resistance

Indexed keywords

AMINO ACID; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; RALTEGRAVIR;

ARTICLE; COCULTURE; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVE SITE; GENETIC CONSERVATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IC 50; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PROTEIN MOTIF; STOP CODON; VIRUS CULTURE; VIRUS ISOLATION; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CATALYTIC DOMAIN; CODON, NONSENSE; COHORT STUDIES; CONSERVED SEQUENCE; DRUG RESISTANCE, VIRAL; FRANCE; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HIV-2; HUMANS; INHIBITORY CONCENTRATION 50; INTEGRASE INHIBITORS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; PYRROLIDINONES; QUINOLONES;

EID: 54549099338     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn335     Document Type: Article

References (32)

1. Withrouw M, Pannecouque C, Switzer WM et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9 57-65.
2. Desbois D, Roquebert B, Peytavin G et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52 1545-8.
3. Tantillo C, Ding J, Jacobo-Molina A et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994; 243: 369-87.
4. Hazuda DJ, Felock P, Witmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646-50.
5. Hazuda DJ, Young SD, Guare JP et al. Integrase inhibitors and cellular immunity suppress retraviral replication in rhesus macaques. Science 2004; 305: 528-32.
6. Zolopa A, Mullen M, Berger D et al. The HIV integrase inhibitor GS-9137 demonstrates potent ARV activity in treatment-experienced patients. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 143LB, p. 119. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
7. Cooper D, Gatell J, Rockstroh J et al. Results of BENCHMRK-1; a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 105aLB, p. 103. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
8. Soriano V, Gomes P, Heneine W et al. Human immunodeficiency virus type 2 (HIV-2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 2000; 61 111-6.
9. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol 2002; 83: 1253-65.
10. Matheron S, Mendoza-Sassi G, Simon F et al. HIV-1 and HIV-2 AIDS in African patients living in Paris. AIDS 1997; 11: 934-6.
11. De Cock KM, Adjorlolo G, Ekpini E et al. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA 1993; 270: 2083-6.
12. Matheron S, Pueyo S, Damond F et al. Factors associated with clinical progression in HIV-2 infected patients: The French ANRS cohort. AIDS 2003; 17.
13. Myers G, Korber BT, Foley BT et al. Human Retroviruses and AIDS 1996: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 1996.
14. D'Aquila FIT, Schapiro JM, Brun-Vézinet F et al. Drug resistance mutations in HIV-1. Top HIV Med 2002; 10: 21-5.
15. Hackett J, Swanson P, Harris B et al. Comprehensive evaluation of HIV-1 integrase gene diversity in group M, N and O viruses. In: Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005. Abstract 366, p. 186. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
16. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007; 12: 563-70.
17. Yerly S, Hirschel B, Gaille C et al. Natural polymorphism of HIV-1 subtypes B and non B integrase gene. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infection, Los Angeles, CA, 2007. Abstract 626, p. 296. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
18. Brun-Vezinet F, Ingrand D, Deforges L et al. HIV-1 sensitivity to zidovudine: A consensus culture technique validated by genotypic analysis of the reverse transcriptase. J Virol Methods 1992; 37 177-88.
19. Damond F, Collin G, Descamps D et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J Clin Microbiol 2005; 43: 4234-6.
20. Van Maele B, Debyser Z. HIV-1 integration: An interplay between HIV-1 integrase, cellular and viral proteins. AIDS Rev 2005; 7: 26-43.
21. Zheng R, Jenkins TM, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci USA 1996; 93: 13659-64.
22. Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem 2004; 4: 965-77.
23. Lu R, Limon A, Ghory HZ et al. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J Virol 2005; 79: 2493-505.
24. Steigbigel R, Kumar P, Eron J et al. Results of BENCHMRK-2; a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infection, Los Angeles, CA, 2007. Abstract 105bLB, p. 104. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
25. Sato M, Motomura T, Aramaki H et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006; 49: 1506-8.
26. Markowitz M, Morales-Ramirez JO, Nguyen BY et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43: 509-15.
27. Fikkert V, Van Maele B, Vercammen J et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol 2003; 77: 11459-70.
28. Fikkert V, Hombrouck A, Van Remoortel B et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 2004; 18: 2019-28.
29. Hazuda D, Miller MD, Nguyen BY et al. Resistance to the HIV-1 integrase inhibitor raltegravir: Analysis of protocol 005 a phase II study in patients with triple class resistant HIV-1 infection. In: Abstracts of the Sixteenth International HIV Drug Resistance Workshop, Barbados, West Indies, 2007. Abstract 8. Antivir Ther 2007; 12 (Suppl. 1): S10.
30. Ceccherini-Silberstein F, Malet I, Fabeni L et al. Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients. In: Abstracts of the Sixteenth International HIV Drug Resistance Workshop, Barbados, West Indies, 2007. Abstract 68. Antivir Ther 2007; 12 (Suppl. 1): S77.
31. Damond F, Lariven S, Roquebert B et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22: 665-6.
32. Garett N, Xu L, Smit E et al. Raltegravir treatment response in an HIV-2 infected patient: A case report. AIDS 2008; 22: 1091-8.